Technology Listings


Methods for the Treatment of a Traumatic Central Nervous System Injury

Application

Use of progesterone for the treatment of traumatic brain injury (TBI).

Key Benefits
  • Progesterone has a demonstrated therapeutic benefit to TBI patients including reduced mortality, and a potential to reduce secondary injury and enhance functional recovery.
  • These compounds are inexpensive, safe for administration to both man and women, and have only minor side-effects in contrast to current therapies.
Technical Summary

According to recent estimates by the Centers for Disease Control and Prevention, approximately 1.4 million people suffer from traumatic brain injury (TBI) annually, and up to 50,000 of these patients die as a result of their condition. Critical to reducing the number of brain injury-related mortalities is the delivery of an effective therapy in the early hours after injury occurs.

This invention provides a method of reducing neurological damage to the brain following traumatic injury or stroke. Sudden shock to the brain disrupts the NMDA, glutamate, cholinergic, acetylcholine, and GABA A receptor systems. Emory scientists have discovered that administration of progesterone or its metabolites provides a neuroprotective effect that inhibits the loss of neuronal activity and minimizes neurodegeneration. Administering progesterone or a progesterone metabolite has been shown to reduce cerebral edema and the inflammatory response, both leading causes of death from traumatic injuries. The consequence of reduced inflammation is a reduction in intracranial pressure, brain swelling, and the decreased subsequent release of neurotoxic substances, which yields a more favorable patient prognosis. Neurosteroids such as progesterone, progestin or aprogestin metabolite can stop microglia from releasing harmful free radicals, modulate the effects of glutamate, stimulate myclin production, and potentiate GABA transmission. A potential result is dramatically improved patient outcome following stroke of head trauma.

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
EP Registered Country Germany 08167618.1 EP2030622B1 3/24/2006 2/23/2011 3/24/2026
EP Registered Country Italy 08167618.1 EP2030622B1 3/24/2006 2/23/2011 3/24/2026
EP Registered Country United Kingdom 08167618.1 EP2030622B1 3/24/2006 2/23/2011 3/24/2026
Nationalized - Based on Foreign IP Hong Kong 08107067.5 HK1112579 3/24/2006 5/3/2013 3/24/2026
EP Registered Country France 08167618.1 EP2030622B1 3/24/2006 2/23/2011 3/24/2026
EP Registered Country Spain 08167618.1 EP2030622B1 3/24/2006 2/23/2011 3/24/2026
EP Registered Country Switzerland 08167618.1 EP2030622B1 3/24/2006 2/23/2011 3/24/2026
EP Registered Country France 06748657.1 1868614 3/24/2006 8/8/2012 3/24/2026
EP Registered Country Germany 06748657.1 1868614 3/24/2006 8/8/2012 3/24/2026
EP Registered Country Italy 06748657.1 1868614 3/24/2006 8/8/2012 3/24/2026
EP Registered Country Switzerland 06748657.1 1868614 3/24/2006 8/8/2012 3/24/2026
EP Registered Country United Kingdom 06748657.1 1868614 3/24/2006 8/8/2012 3/24/2026
Divisional Japan 2013-263682 5496407 3/24/2006 3/14/2014 3/24/2026
Nationalized PCT - Foreign Japan 2008-503227 5295755 3/24/2006 6/21/2013 3/24/2026
Nationalized PCT - Foreign Australia 2006226811 2006226811 3/24/2006 3/10/2011 3/24/2026
Nationalized PCT - Foreign Canada 2,601,715 2,601,715 3/24/2006 10/16/2012 3/24/2026
Divisional EP 08167618.1 EP2030622B1 3/24/2006 2/23/2011  
Nationalized - Based on Foreign IP Hong Kong 09107489.4 HK1128242 3/26/2006 4/29/2011 3/26/2026
Tech ID: 05059
Published: 10/8/2014
Category
Therapeutics

Contact
Justin Burns
Licensing Associate
Emory University
justin.burns@emory.edu

Inventor(s)
Donald Stein
Arthur Kellermann
David Wright
Stuart Hoffman
Douglas Lowery

Keywords
Neuroscience/Pain